Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

PF-08046033: Advancing GPNMB Targeted Auristatin-S ADC Through Payload Modification to Improve Tolerability

By | 8 June 2026

Explaining development rationale for GPNMB-targeted Auristatin-S ADCs informed by the historical therapeutic index constraints observed with vedotin-based ADCs
Outlining preclinical data showing Auristatin-S ADC preserved potency, improved tolerability and a wider therapeutic window
Exploring opportunity to enable higher dosing and improve clinical benefit in NSCLC, esophageal cancer, head and neck cancers and melanoma